British health chiefs have quietly released a warning that Pfizer and Moderna’s Covid vaccines may cause heart damage, MailOnline can reveal.
Fears about the mRNA jabs’ links to myocarditis have grown in recent weeks, following a string of cases in young adults and children in Israel and the US.
mRNA
Browse the articles related to this topic below.
Join our community on Guilded.
Whitney Webb is interviewed by the Investigative Corona Committee Germany about who is influencing the conversation around COVID-19. Her interview starts at 1h09m.
Interview notes:
- Google Ventures’ investment in the AstraZeneca vaccine via Vaccitech.
- Reworking of the healthcare system and replacement of doctors with artificial intelligence.
- The ties between government, Big Tech, the military, healthcare and artificial intelligence.
- The AstraZeneca-Oxford vaccine is not non-profit. The two developers at the Jenner Institute, Sarah Gilbert and Adrian Hill, have a company, Vaccitech, on which the technology is based.
- The British Government has directly invested in Vaccitech and is expected a profit.
- The other main stakeholder is Bravos Capital (through Oxford Science Innovation), which was set up by former head of Global Equity Trading at Deutsche Bank.
- The German Government has invested money in CureVac BioNTech vaccine. 20% of the shares is owned by the German Government.
- Sequoia Capital‘s Chinese Branch, Fosun Pharma and The Wellcome Trust (through Oxford Science Innovation) are also investors in Vaccitech.
- The Wellcome Trust is the institution that is most involved in the AstraZeneca vaccine.
- The Jenner Institute is conducting trials in Africa for a universal malaria vaccine and they have a nasty track-record of not being honest about their trials. They lied about risks and infants died.
- The Jenner Institute was a public-private partnership with GlaxoSmithKline and the UK Government in the 1990s. They are one of the main vehicles at Oxford University for vaccine development and also UK vaccine funding research.
- Adrian Hill, the head of the Jenner Institute, is the chief at the UK Government’s UK Vaccine Network which decides which technology to research, fund and give to the population both in the UK and globally through vaccine philanthropy.
- COVAX, The Bill & Melinda Gates Foundation effort to vaccinate the developing world, relies almost entirely on AstraZeneca.
- Johnson & Johnson is being manufactured by Emergent BioSolutions which previously was called BioPort.
- BioPort was a spin-off of a fusion between Porton Down, the UK’s bio-defence lab (Defence Science and Technology Laboratory), and the between [William_J._Crowe] the former head of the Joint Chiefs of Staff under US President Ronald Regan.
- Emergent BioSolutions/BioPort was chosen to manufacture the Johnson & Johnson vaccine despite many scandals.
- The person in-charge of quality control for the Johnson & Johnson vaccine has no experience in the field. His background is head of Military Intelligence teams for the US Military in Iraq and Afghanistan and is also an expert on Iran and North Korea.
- Emergent BioSolutions are intimately connected to the CIA and Bechtel Corporation which has ties to the anthrax attacks in the US.
- Dr. Wodarg raised the possibility that the current situation is being used to covertly study wide use mRNA vaccines.
- Pfizer and Moderna mRNA technology was started with significant investment from DARPA in 2013.
- In 2016, Moderna was the most highly valued biotech company in the US but had no products.
- Regina Dugan greenlighted the investments from DARPA and later left in 2012 to create a DARPA-equivalent for Google and Facebook. She has now teamed up with the Wellcome Trust to create a ‘global health DARPA-equivalent’.
- Some discussion on the pre-911 anthrax vaccine and anthrax attack scandal, with links to reporter Judith Miller who was later involved in the Dark Winter simulation in June 2001.
- A lot of the same people who produced the Dark Winter simulation are the same people who oversaw Event 201 simulation.
- Dr. Wodarg raised concerns about the experimentation with lipid nanoparticles.
- There is a clear push to ‘remake healthcare’ from Silicon Valley towards AI healthcare and Precision Medicine, which is medications, vaccines and gene therapy targeted to the individual.
- A lot of COVID-19 testing in the Western US has been done by Google subsidiary Verily Life Sciences.
- AI healthcare and Precision Medicine is being co-developed by Google and the US military’s Defense Innovation Unit.
- Dr. Wodarg observed that we are seeing the unveiling of a long developed strategy.
- The push in medicine for gene editing goes back to Julian Huxley, first Director General of UNESCO and former president of the British Eugenics Society (renamed in 1989 to the Galton Institute). Julian Huxley, brother of Aldous Huxley, said in 1946 that we should, “make the unthinkable thinkable again” and also coined the term Transumanism. He said that gene editing as a eugenics science needed to be applied along with efforts to merge humans with machines in order to create a ‘new human being’. This goes back to 1957.
- Adrian Hill of the AstraZeneca vaccine spoke at the Galton Institute’s 100 Year Anniversary. The Wellcome Trust hosts their archive.
- Julian Huxley’s speech about “making the unthinkable thinkable again” was in connection with the founding of UNESCO.
- The push for Precision Medicine is ultimately about control and eugenics.
- The Obama Administration funded a lot of the Precision Medicine initiatives. The Biden Administration is creating a ‘health DARPA’ which will be led by Eric Lander (who has ties with Jeffrey Epstein).
- Jeffrey Epstein wanted the seed the human race with his own DNA. The scientists Epstein funded are still around. One of them is Harvard genetecist George Church who has openly promoted unethical human experimentation and eugenics.
- The Edge Foundation was operating as a front for Epstein as a way to gain influence in Silicon Valley, science and academia. His main handler is probably the Mega Group. He has ties with Isabelle Maxwell (Gislane Maxwell’s sister) who is a World Economic Forum technology pioneer.
- Bill Gates‘ ties with Epstein looks to go back to the 1990s. A 2001 Evening Standard article claims that Epstein’s main business partners were Leslie Wexner, Donald Trump and Bill Gates. Microsoft as a company may have been compromised by the same intelligence networks that Epstein operated in.
- Yuval Noah Harari: soon there will be an age of digital dictators and humans have been reduced to ‘hackable animals’ through technology.
- Klaus Schwab openly talks about COVID-19 being the catalyst for The Great Reset and Transhumanism. The fear of COVID would give way to the fear of Climate Change and Cyber Pandemic.
Backup mirrors:
Dr. Robert Malone, inventor of the mRNA technology used in the COVID-19 injections, discusses his concerns over their safety and how concerns are censored.
- “I have been written out of history.”
- The chairman of the board of Reuters sits on the board of Pfizer.
- The conflicts of interests are overt…it’s in your face…they have no shame.
- The big thinkers in the government envy the Chinese model of government.
- The political spectrum is irrelevant [on the topic of COVID and vaccines].
- These discussions are forbidden talk so we won’t get to the truth.
- Detailed discussion on the cytotoxic effects of spike proteins and safety of the new mRNA COVID vaccines at around 40mins.
- Dr. Malone agrees with many of Dr. Mike Yeadon‘s comments, except Dr. Yeadon’s conclusion of a conspiracy.
- The figure of 70% uptake of vaccines to reach herd immunity was made up. The data isn’t known. “Somebody is just pulling it out of the air.”
- The vaccines don’t stop you from getting the virus or spreading it.
- The early trials were designed to optimise success.
- You cannot publish stuff outside of the approved memes and that means we can’t do science. People are dying because of this.
- Other treatments have been suppressed to increase uptake of the vaccine.
- The fear is bringing out social pathologies and is diminishing our ability to think.
- We’ve had rampant groupthink in the government, in the WHO and across the world.
- “I’ve never seen this level of co-ordinated crazy.”
- “I’m concerned about what’s at the other side of the tunnel.”
- The new COVID-19 vaccines are still experimental.
- “Most of us who haven’t drunk the Koolaid” say the risk of COVID to children is remarkably low and the risk of vaccines is not nothing.
- There is no logic in vaccinating children, adolescents and young adults. There are some risk and they’re not trivial.
Source links can be found at The Last American Vagabond.
THE CENTERS for Disease Control and Prevention’s safety committee has provided an update on the association between Pfizer-BioNTech and Moderna COVID-19 vaccines and heart inflammation.
On 23 June the US Centers for Disease Control and Prevention’s safety committee said there was a “likely association” between the Pfizer-BioNTech and Moderna COVID-19 vaccines and myocarditis (the medical term for heart inflammation) and pericarditis (inflammation of the tissue that surrounds the heart) in some young adults. The CDC’s Advisory Committee on Immunization Practices said there was a higher than expected number of reports of heart inflammation in people aged 16-24 who had received the mRNA vaccines but that the benefits of vaccination still clearly outweighed the risks.
The world’s richest medical research foundation, the Wellcome Trust, has teamed up with a pair of former DARPA directors who built Silicon Valley’s skunkworks to usher in an age of nightmarish surveillance, including for babies as young as three months old. Their agenda can only advance if we allow it.
https://unlimitedhangout.com/2021/06/investigative-reports/a-leap-toward-humanitys-destruction/
Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy.
The present assessment raises the question whether it would be necessary to rethink policies and use COVID-19 vaccines more sparingly and with some discretion only in those that are willing to accept the risk because they feel more at risk from the true infection than the mock infection. Perhaps it might be necessary to dampen the enthusiasm by sober facts? In our view, the EMA and national authorities should instigate a safety review into the safety database of COVID-19 vaccines and governments should carefully consider their policies in light of these data. Ideally, independent scientists should carry out thorough case reviews of the very severe cases, so that there can be evidence-based recommendations on who is likely to benefit from a SARS-CoV2 vaccination and who is in danger of suffering from side effects. Currently, our estimates show that we have to accept four fatal and 16 serious side effects per 100,000 vaccinations in order to save the lives of 2–11 individuals per 100,000 vaccinations, placing risks and benefits on the same order of magnitude.
SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization and are likely an important component of natural immunity, however, limited information exists on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine dose IgG levels increased further, reaching a maximum approximately 7–10 days later, and remained elevated (average of 58% peak levels) during the additional >100 day follow up period. COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction and time to peak levels, but more rapid decline in serum levels following both the 1st and 2nd vaccine doses (<18% peak levels within 100 days of the 2nd shot). The data demonstrate COVID-19 mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked differences in their persistence in serum.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249499
Manufacturers have been granted exemption from liability for any resulting harm. Ruud Dobber, a member of AstraZeneca’s senior executive team, said: “This is a unique situation where we as a company simply cannot take the risk if in … four years the vaccine is showing side effects.” (The government has taken on the liability and has an insurance scheme in place.)
https://www.thetimes.co.uk/article/why-not-giving-children-covid-vaccine-lw5kpn5m5
A higher-than-expected number of young men have experienced heart inflammation after their second dose of the mRNA COVID-19 shots from Pfizer/BioNTech and Moderna, according to data from two vaccine safety monitoring systems, the U.S. Centers for Disease Control and Prevention (CDC) said on Thursday.
…There were 283 observed cases of heart inflammation after the second vaccine dose in those aged 16 to 24 in the VAERS data. That compares with expectations of 10-to-102 cases for that age range based on U.S. population background incidence rates, the CDC said.
Accurate information about the development and production of COVID-19 vaccines is essential, especially because many proposed candidates use newer molecular technologies for production of a viral vaccine. One concern regarding the ethical assessment of viral vaccine candidates is the potential use of abortion-derived cell lines in the development, production or testing of a vaccine. This analysis utilizes data from the primary scientific literature when available, along with data from clinical trial documents, reputable vaccine tracking websites, and published commercial information.1 It is the hope that by providing accurate data, recipients can make well-informed decisions regarding vaccine choices.
| Analysis of SARS-CoV-2 (COVID-19) Vaccine Candidates
Last Updated 2 June 2021
|
 DOES NOT USE abortion-derived cell line
� Currently undetermined |
||||||
| Sponsor(s)1 | Country | Strategy2 | Clinical Trial Status3 | Public Funding4 | Design & Development | Production | Confirm-atory Lab Tests |
| WHOLE VIRUS VACCINE – LIVE ATTENUATED or INACTIVATED | |||||||
| Beijing Institute of Biological Products/ Sinopharm | China | Inactivated virus
“BBIBP-CorV” Given: Intramuscular 2 doses (3 weeks apart) |
WHO granted Emergency Use Listing (EUL) 7May2021
Early approval in China |
Vero monkey cells Wang et al., Cell 182, P713, 6Aug2020
|
Vero monkey cells Wang et al., Cell 182, P713, 6Aug2020
|
Cytopathic test Vero monkey cells |
|
| Wuhan Institute of Biological Products/ Sinopharm | China | Inactivated virus
“New Crown COVID-19” Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3
Early approval in China |
Vero monkey cells |
Vero monkey cells |
Plaque reduction neutralization test Vero monkey cells Xia et al., JAMA 324, 951, 13Aug2020 |
|
| Bharat Biotech/Indian Council of Medical Research | India | Inactivated virus “BBV152” Given: Intramuscular 2 doses (2 weeks apart) |
India EUA granted |
Vero monkey cells |
Vero monkey cells |
Antibody ELISA Plaque reduction Vero monkey cellsYadav et al., ResearchSquare 10Sept2020 |
|
| Institute of Medical Biology, Chinese Academy of Medical Sciences | China | Inactivated virus “SARS-CoV-2 vaccine” Given: Intramuscular 2 doses (2 weeks apart) |
Phase 3 |
Vero monkey cells |
Vero monkey cells |
Antibody ELISA Neutralizing antibody cytopathic effect Vero monkey cells Pu et al., medRxiv, 6Oct2020 Supplement |
|
| John Paul II Medical Research Institute | USA | Live attenuated virus
|
Pre-clinical |
|
|
� | |
| Research Institute for Biological Safety Problems | Kazakhstan | Inactivated virus
“QazCovid-in” Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 | � | � | � | |
| Sinovac Biotech Co., Ltd. | China | Inactivated virus
“CoronaVac” Given: Intramuscular 2 doses (2 weeks apart) |
WHO granted Emergency Use Listing (EUL) 1June2021 China granted conditional marketing authorization 8Feb2021 Early approval in China |
Vero monkey cells
|
Vero monkey cells |
protein test HEK293 cells |
|
| Valneva and Dynavax | France USA UK |
Inactivated Virus “VLA2001” plus adjuvant CpG1018 Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 |
Vero monkey cells
|
Vero monkey cells |
� | |
| VIRAL VECTOR-BASED VACCINE | |||||||
| Altimmune | USA | Replication-deficient
Adenovirus vector “AdCOVID” Given: Intranasal |
Phase 1/2 |
PER.C6 cells |
PER.C6 cells |
|
|
| AstraZeneca
University of Oxford
|
USA
UK |
Replication-deficient
Adenovirus vector “AZD1222” “ChAdOX1nCoV-19” Given: Intramuscular 2 doses (4 weeks apart) |
WHO granted Emergency Use Listing (EUL) on 15Feb2021
India EUA granted |
Operation Warp Speed
HHS-BARDA $1.2 Billion CEPI up to $384 Million |
HEK293 cells |
HEK293 cells |
HEK293 cellsvan Doremalen et al., Nature, 30July2020 MRC-5 cells Almuqrin et al., ResearchSquare 20Oct2020 |
| CanSino Biologics, Inc.
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China |
China | Replication-deficient
Adenovirus vector “Ad5-nCoV” Given: Intramuscular 1 dose |
EUA in Chile, Hungary, Pakistan, Mexico |
HEK293 cells |
HEK293 cells |
|
|
| Gamaleya Research Institute | Russia | Replication-deficient
Adenovirus vectors (rAd26-S+rAd5-S) “Gam-COVID-Vac” “Sputnik V” Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3
EUA in 39 countries as of Mar2021 Early approval in Russia August 2020 |
HEK293 cells |
HEK293 cells |
|
|
| ImmunityBio and NantKwest | USA | Replication-deficient Adenovirus vector recombinant “hAd5 S-Fusion + N-ETSD” Given: Subcutaneous |
Phase 1/2 | E.C7 cells (derivative of HEK293 cells) Rice et al., bioRxiv 30July2020 |
E.C7 cells |
Protein and antibody tests HEK293T cells Rice et al., bioRxiv 30July2020 Seiling et al., medRxiv 6Nov2020 |
|
| Institut Pasteur and Themis and Merck | USA
France |
Replication-competent recombinant measles virus
“TMV-083” Given: Intramuscular |
Development Discontinued Phase 1/2Phase 1 |
CEPI up to $4.9 Million | HEK293T
Development and rescue of recombinant measles virus “SARS-CoV-2 S-encoding vaccine candidates… were generated as described previously” |
Vero monkey cells |
Lentiviral vectors for antigenic DCFusogenic testHEK293TFusogenic testS protein expressionVero monkey cellsHörner et al., PNAS 22Dec2020Hörner et al. Supplement |
| Israel Institute for Biological Research (IIBR) | Israel | Replication-competent recombinant vesicular stomatitis virus (VSVΔG) “IIBR-100” Given: Intramuscular1 dose |
Phase 1/2 | BHK hamster cells Vero monkey cells Yahalom-Ronen et al., bioRxiv 19June2020 |
Vero monkey cells Yahalom-Ronen et al., bioRxiv 19June2020 |
Plaque reduction; immunofluorescence Vero monkey cells Yahalom-Ronen et al., bioRxiv 19June2020 |
|
| Janssen Research & Development, Inc.
Johnson & Johnson |
USA | Replication-deficient
Adenovirus vector “Ad26.COV2-S” 1 dose |
FDA Emergency Use Authorization Approved | Operation Warp Speed
HHS-BARDA $1,457,887,081 total |
PER.C6 cells |
PER.C6 cells |
|
| Laboratorio Avi-Mex | Mexico | Live recombinant Newcastle Disease Virus
Expressing spike-fusion chimeric protein “Patria” Given: Intramuscular or Intranasal |
Phase 1 |
Bacterial cells BSRT7 hamster cells |
�
Chicken eggs |
�
Neutralization Assay Vero monkey cells |
|
| Meissa Vaccines, Inc. | USA | Live attenuated recombinant RSV viral vector
“MV-014-210” Given: Intranasal 1-3 doses (5 weeks apart) |
Phase 1 | |
Vero monkey cells Spike expressing, |
� | |
| Rega Institute, KU Leuven | Belgium | Replication-competent attenuated yellow fever vaccine (YF17D) vector
“YF-S0” Given: Intramuscular |
Pre-clinical |
BHK-21J hamster cells |
BHK-21J hamster cells |
Antibody titer Pseudovirus HEK293T cells Immunoblot BHK-21J hamster cells Sanchez-Felipe et al., Nature, 1Dec2020 |
|
| ReiThera | Italy | Replication-deficient simian adenovirus encoding S
“GRAd COV2” Given: Intramuscular 1 dose |
Phase 2/3 |
HEK293T cells Development and rescue of recombinant |
HEK293T cells |
HEK293T cells |
|
| Merck and IAVI | USA | Replication-competent recombinant vesicular stomatitis virus (VSVΔG)
“V590” Given: Intramuscular |
Development Discontinued Phase 1 |
Operation Warp Speed
HHS-BARDA $38,033,570 |
Vero monkey cells |
Vero monkey cells |
� |
| Shenzhen Geno-immune
Medical Institute |
China | Lentivirus minigenes +
Adult human APC (antigen-presenting cells) “COVID-19/aAPC” Given: Subcutaneous 3 doses (2 weeks apart) |
Phase 1 | � | |
� | |
| Shenzhen Geno-immune
Medical Institute |
China | Lentivirus minigenes +
Adult human CD/T cells (dendritic cells and T cells) “LV-SMENP-DC” Given: Subcutaneous and Intravenous 1 dose |
Phase 1/2 | � | |
� | |
| Vaxart | USA | Replication-deficient
Adenovirus vector “VXA-CoV2-1” plus dsRNA adjuvant Given: Oral 2 doses (4 weeks apart) |
Phase 1 |
HEK293 cells |
HEK293 cells |
|
|
| PROTEIN-BASED VACCINE | |||||||
| Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences | China | Protein vaccine
Recombinant RBD dimer plus adjuvant ”ZF2001” Given: Intramuscular 2 or 3 doses (28 days apart) |
Phase 3 |
HEK293T cells |
CHO hamster cells |
Pseudovirus HEK293T cells |
|
| Clover Biopharmaceuticals, Inc. | China | Protein vaccine
“SCB-2019” plus adjuvant CpG 1018 Given: Intramuscular |
Phase 2/3 | CEPI up to $69.5 Million | cDNA in expression vector; transfect CHO hamster cells
|
CHO hamster cells |
PseudovirusHEK293 cellsRef’d: Nie et al., Emerging Microbes & Infections 24Mar2020Cytopathic effect Vero monkey cellsLiang et al., bioRxiv, 24Sept2020 |
| COVAXX and United Biomedical | USA Taiwan |
Protein vaccine
“UB-612” S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP) Given: Intramuscular |
Phase 2/3 | cDNA in expression vector; transfect CHO hamster cells
|
CHO hamster cells |
Antibody blocked binding to hACE2 HEK293 Guirakhoo et al., bioRxiv, 30Nov2020 |
|
| Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vektor” | Russia | Protein vaccine “EpiVacCorona” chemically synthesized peptide antigens of SARS-CoV-2, conjugated to a carrier protein adsorbed on an aluminum-containing adjuvant Given: Intramuscular2 doses (3 weeks apart) |
Phase 3
Early approval in Russia Oct 2020 |
� |
chemically synthesized peptide antigens |
� | |
| Instituto Finlay de Vacunas | Cuba | Protein vaccine “Finlay-FR-1” (“Soberana 01”) Receptor-binding domain (RBD) SARS-CoV-2 spike + adjuvant Given: Intramuscular2 doses (4 weeks apart) |
Phase 1/2 Phase 1 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� | |
| Instituto Finlay de Vacunas | Cuba | Protein vaccine “Finlay-FR-2” (“Soberana 02”) Receptor-binding domain (RBD) SARS-CoV-2 spike chemically bound tetanus toxoid + adjuvant Given: Intramuscular2 doses (4 weeks apart) |
Phase 2 Phase 1 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� RBD produced in mammalian cells Garcia-Rivera, MEDICC Review, 30Oct2020 |
� | |
| John Paul II Medical Research Institute | USA | Recombinant Protein
Perinatal human cells (term umbilical cord and placental) |
Pre-clinical |
|
|
� | |
| Kentucky BioProcessing, Inc. (British American Tobacco) |
USA | Protein vaccine “KBP-201” Plant-expressed RBD Given: Intramuscular2 doses (3 weeks apart) |
Phase 1/2 |
Recombinant DNA sequence for RBD of SARS-CoV-2 |
Plant expression of RBD peptide |
� | |
| Medicago | Canada | Protein on Virus-Like Particle
“CoVLP” Plant-expressed spike protein particle with adjuvant, CpG1018 or AS03 Given: Intramuscular 2 doses (3 weeks apart) |
Phase 2/3 |
Recombinant DNA sequence in Agrobacterium, transformation of plant cells |
Plant expression of protein and VLP |
Pseudovirus HEK293 cells |
|
| Migal Galilee Research Institute | Israel | Protein vaccine
E. coli expressed chimeric S and N proteins Given: Oral |
Pre-clinical | � |
Bacterial production system |
� | |
| Novavax | USA | Protein vaccine
“NVX-CoV2373” Baculovirus expression plus Matrix M adjuvant Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 | Operation Warp Speed
HHS-BARDA $1,600,434,523 CEPI up to $388 Million |
|
Sf9 insect cells |
Pseudovirus HEK293 cells |
| Sanofi and GSK
Protein Sciences
|
USA
France |
Protein vaccine
Baculovirus expression plus AS03 adjuvant Given: Intramuscular 2 doses (3 weeks apart) |
Phase 3 | Operation Warp Speed
HHS-BARDA $2,072,775,336 total |
Recombinant baculovirus |
Sf9 insect cells |
Pseudovirus HEK293T cells |
| Sorrento | USA | Protein vaccine
“T-VIVA-19” SARS-Cov-2 spike protein S1 domain fused with human IgG-Fc Given: Intramuscular |
Pre-clinical | |
CHO cells |
Antibody ELISA; Neutralization assays Vero monkey cells |
|
| Sorrento | USA | Protein vaccine
“STI-6991” SARS-Cov-2 spike protein expressed on K562 cells |
Pre-clinical | � |
K562 cells |
� | |
| University of Pittsburgh | USA | Protein vaccine
Adenovirus-expressed recombinant proteins “PittCoVacc” Given: Microneedle arrays |
Pre-clinical |
HEK293 cells |
HEK293 cells |
|
|
| University of Queensland and CSL Ltd. | Australia | Protein vaccine
“V451” Recombinant protein with proprietary molecular clamp Given: Intramuscular |
HALTED | CEPI up to $4.5 Million | |
expiCHO hamster cells
|
� |
| Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and Development Command | USA | Protein vaccine
”SpFN” Spike-Ferritin nanoparticle with ALFQ adjuvant Given: Intramuscular 2-3 doses (4 weeks apart; plus 6 months after initial injection) |
Phase 1 |
Expi293 cells |
Expi293 cells |
Pseudovirus HEK293 cells Virus neutralization Vero monkey cells |
|
| RNA VACCINE | |||||||
| Arcturus Therapeutics | USA | mRNA vaccine
self-transcribing, replicating “LUNAR-CoV19” (“ARCT-021”) in vitro transcription reaction with T7 RNA polymerase from STARR plasmid template LUNAR proprietary lipid nanoparticle encapsulated Given: Intramuscular 1 dose |
Phase 2
|
Sequence designed on computer |
No cells used |
protein test HEK293 Protein expression Hep3b cells Plaque reduction neutralization Vero monkey cells |
|
| CureVac | Germany | mRNA vaccine
non-replicating “CVnCoV” in vitro transcription lipid nanoparticle encapsulated Given: Intramuscular 2 doses (4 weeks apart) |
Phase 3 | CEPI up to $15.3 Million |
Sequence designed on computer |
No cells used |
Protein test Reticulocyte lysate, |
| Imperial College London | UK | mRNA vaccine
Self-amplifying ”LNP-nCoVsaRNA” in vitro transcription lipid nanoparticle encapsulated Given: Intramuscular 2 doses |
Phase 1 |
Expression plasmid HEK293 cells |
No cells used |
Pseudovirus HEK293T cells |
|
| Moderna, Inc.
with National Institutes of Health |
USA | mRNA vaccine
non-replicating “mRNA-1273” T7 RNA polymerase-mediated transcription from DNA plasmid template LNP (lipid nanoparticle) encapsulated Given: Intramuscular 2 doses (4 weeks apart) |
FDA Emergency Use Authorization Approved | Operation Warp Speed
HHS-BARDA $2,479,894,979 total CEPI up to $1 Million |
Sequence designed on computer |
No cells used |
protein test & pseudovirus HEK293 cells Plaque reduction neutralization Vero monkey cells |
| Pfizer and BioNTech | USA
Germany |
mRNA vaccine
non-replicating “BNT-162a1,b1,b2,b3,c2” nucleoside-modified mRNA in vitro transcribed by T7 polymerase from a plasmid DNA template LNP (lipid nanoparticle) encapsulated Given: Intramuscular 2 doses (3 weeks apart) |
FDA Emergency Use Authorization Approved
UK EUA granted
|
Operation Warp Speed
HHS-BARDA $1.95 Billion |
Sequence designed on computer |
No cells used |
protein test & pseudovirus HEK293 cells Neutralization assay Vero monkey cells |
| Providence Therapeutics | Canada | mRNA vaccine
“PTX-COVID19-B” mRNA in vitro transcription from plasmid template using T7 RNA polymerase Given: Intramuscular 2 doses (4 weeks apart) |
Phase 1 |
HEK293T cells used to select mRNA candidate |
No cells used |
Pseudovirus, serum neutralization HEK293T cells Vero monkey cells |
|
| Sanofi Pasteur and
Translate Bio |
USA
France |
mRNA vaccine
non-replicating “MRT5500” synthesized by in vitro transcription employing RNA polymerase with a plasmid DNA template LNP (lipid nanoparticle) encapsulated Given: Intramuscular 2 doses (3 weeks apart) |
Phase 1/2 |
HEK293T cells used to select mRNA candidate |
No cells used Kalnin et al., npj Vaccines 19Apr2021 |
protein test & pseudovirus HEK293 cells |
|
| DNA VACCINE | |||||||
| Genexine | Korea | DNA vaccine
“GX-19” DNA synthesized in vitro, placed in plasmid vector Given: Intramuscular and Electroporation 2 doses (4 weeks apart) |
Phase 1/2 |
Sequence designed on computer |
No cells used |
No cells used
|
|
| Inovio Pharmaceuticals | USA | DNA vaccine
“INO-4800” DNA synthesized in vitro, placed in plasmid vector Given: Intradermal Electroporation 2 doses (4 weeks apart) |
Phase 2/3 | Operation Warp Speed
CEPI up to $22.5 Million |
Sequence designed on computer |
No cells used |
protein test & pseudovirus HEK293 cells |
| Osaka University, AnGes, Takara Bio | Japan | DNA vaccine
“AG0301-COVID19” 2 doses (2 weeks apart) |
Phase 2/3 |
Sequence designed on computer |
No cells used |
Virus neutralization Vero E6 cells monkey cells |
|
| Symvivo Corporation | Canada | DNA vaccine
“bacTRL-spike” Given: Oral, bacteria bind to gut lining 1 dose |
Phase 1 | � |
No cells used |
� | |
| Zydus Cadila | India | DNA vaccine
“ZyCov-D” 3 doses (4 weeks apart) |
Phase 3 |
Sequence designed on computer |
No eukaryotic cells used |
Expression analysis |
|
Alex talks with Dr. Byram Bridle, an Associate Professor on Viral Immunology at the University of Guelph about new peer-reviewed studies that suggests there may be terrifying reasons side effects such as heart inflammation, VITT (Vaccine induced Thrombosis and Thrombocytopenia) , and other serious issues may occur in those who have been vaccinated.
- New scientific information that has helped us understand why the vaccine problems are happening.
- This is backed up by well-known peer-reviewed scientific publications.
- SARS-CoV-2 has a spike protein on its surface which is what it allows us to infect our bodies.
- Vaccines get the cells in our body to manufacture the spike protein.
- In theory, if we can mount an immune response to this protein, we can prevent the virus from infecting the body.
- When studying the disease, cardio-vascular problems, bleeding and clotting have been associated with severe COVID-19.
- The spike protein is almost entirely responsible for the damage to the cardio-vascular system.
- If you inject the purified spike protein into blood of lab animals, they get all sorts of damage to the cardio-vascular system.
- The assumption up until know is that the new COVID-19 vaccinations behave like other vaccines: they stay at the injection site.
- However, a FOI request has revealed a bio-distribution study that shows the spike protein of the new COVID-19 vaccines gets into the blood post-vaccination and accumulate in tissues such as the spleen, bone marrow, liver, adrenal glands and ovaries.
- It’s been known for a long time that the spike protein is a pathogenic protein–it’s a toxin.
- We now have evidence that the new vaccines gets into blood circulation. When in circulation, the spike protein can bind to the receptors on our platelets and the cells that line our blood vessels.
- When this happens, it can either cause clotting or bleeding.
- It can cross the blood-brain barrier and cause neurological damage.
- There is also evidence that the antibodies can be transferred through breast milk (study not yet accepted). The could be evidence that suckling infants experiencing bleeding disorders in the gastrointestinal tract.
- This has implications for blood donations, sucking infants and people who are not at risk from COVID-19–that includes all our children.
- We made a big mistake. We thought the spike protein was a great target antigen. We didn’t know the spike protein itself was a pathogenic protein.
- By vaccinating people we are inadvertently inoculating them with a toxin that can cause damage.
- Will we be rendering young people infertile?
https://omny.fm/shows/on-point-with-alex-pierson/new-peer-reviewed-study-on-covid-19-vaccines-sugge
Backup mirror:
Dr. Hodkinson, here to discuss the dangers of the COVID-19 vaccines, the possibility of infertility, and the very real concerns about the vaccine-induced spike proteins and what new scientific research is clearly suggesting about their risks to your health.
CDC looking into reports that a small number of teens and young adults vaccinated against the coronavirus that may have experienced heart problems
Condition, known as myocarditis, results in an inflammation of the heart muscle which can occur following certain infections
Problems have been occurring four days after the second dose has been given
Dozens of cases have been reported to the agency in recent week
It is not yet clear which vaccine might be responsible, Moderna or Pfizer
The agency’s vaccine safety group was sparse in details, saying only that there were ‘relatively few’ cases and levels were similar to normal
Group also said that the conditions may be entirely unrelated to vaccination
Citizens subjected to punitive restrictions on their liberties and movement for more than 12 months, are now being forced into mass, and what will soon be, mandatory vaccination programs to gain back their freedoms. Political leaders continue use the vacuous and dishonest slogan of “following the science” that many still believe, but are they leading us into another form of hell?
The Covid-19 vaccines are new vaccines and only provisionally approved. They are still in the trial phase which ends at earliest in 2023. Brilliant they may well be, and enormously enriching for their investors, but are our Government’s providing the facts for informed choice in vaccination? Are there other risks to their rushed vaccine rollouts, including to front line medical and essential service workers? And why are so many eminent scientists and influential community leaders in our countries being silenced by social and mainstream media?
The Victorian Government recently commissioned a paper entitled Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. We are not hopeful but will attempt to discuss the paper with one of its authors in another episode.
In the meantime, to talk about mRNA vaccines and Antibody Dependent Enhancement is Professor Dolores Cahill, a renown expert in immunology and the study of immune systems.
Dr. Cahill is a Professor of University College Dublin and was Group Leader of the Max-Planck-Institute in Berlin, Germany from 1995 to 2003. She is an Inventor, Founder and Shareholder of companies and has international Patents with applications for improving the early diagnosis of diseases such as auto immune diseases & cancer.
Dr. Cahill has been an Expert in the EU for some 15 years in Future & Emerging technologies. Professor Cahill’s latest business ventures include the World Freedom Alliance, a worldwide platform of organisations offering access to justice, true dialogue for health science and politics, holding worldwide officials to account under the law. The World Freedom Alliance offers transparent evidence-based solutions and encourages robust debate with media, scientists and governments to ensure fundamental freedoms for people of the world.
Hard to justify right now for most children in most countries
Following widespread vaccination against SARS-CoV-2 of older adults and other highly vulnerable groups, some high income countries are now considering vaccinating children; just days ago, the US Food and Drug Administration authorized the use of the Pfizer/BioNTech vaccine in children 12-15 years of age. Young people have been largely spared from severe covid-19 so far, and the value of childhood vaccination against respiratory viruses in general remains an open question for three reasons: the limited benefits of protection in age groups that experience only mild disease; the limited effects on transmission because of the range of antigenic types and waning vaccine induced immunity; and the possibility of unintended consequences related to differences in vaccine induced and infection induced immunity. We discuss each in turn.
Many of the vaccines developed to protect against COVID-19 are forms of messenger RNA (mRNA) vaccines.
The Moderna and Pfizer/BioNTech vaccines are forms of mRNA vaccine.
Unlike the Pfizer/BioNTech and Moderna coronavirus vaccines, the Oxford/AstraZeneca vaccine is not an mRNA vaccine.
Instead, the AstraZeneca vaccine is a viral vector vaccine made from a weakened form of a common cold virus from chimpanzees.
Among 827 participants who had a completed pregnancy, the pregnancy resulted in a live birth in 712 (86.1%), in a spontaneous abortion in 104 (12.6%), in stillbirth in 1 (0.1%), and in other outcomes (induced abortion and ectopic pregnancy) in 10 (1.2%). A total of 96 of 104 spontaneous abortions (92.3%) occurred before 13 weeks of gestation (Table 4), and 700 of 712 pregnancies that resulted in a live birth (98.3%) were among persons who received their first eligible vaccine dose in the third trimester. Adverse outcomes among 724 live-born infants — including 12 sets of multiple gestation — were preterm birth (60 of 636 among those vaccinated before 37 weeks [9.4%]), small size for gestational age (23 of 724 [3.2%]), and major congenital anomalies (16 of 724 [2.2%]); no neonatal deaths were reported at the time of interview. Among the participants with completed pregnancies who reported congenital anomalies, none had received Covid-19 vaccine in the first trimester or periconception period, and no specific pattern of congenital anomalies was observed. Calculated proportions of pregnancy and neonatal outcomes appeared similar to incidences published in the peer-reviewed literature
A previously symptomless 86-year-old man received the first dose of the BNT162b2 mRNA COVID-19 vaccine. He died 4 weeks later from acute renal and respiratory failure. Although he did not present with any COVID-19-specific symptoms, he tested positive for SARS-CoV-2 before he died. Spike protein (S1) antigen-binding showed significant levels for immunoglobulin (Ig) G, while nucleocapsid IgG/IgM was not elicited. Acute bronchopneumonia and tubular failure were assigned as the cause of death at autopsy; however, we did not observe any characteristic morphological features of COVID-19. Postmortem molecular mapping by real-time polymerase chain reaction revealed relevant SARS-CoV-2 cycle threshold values in all organs examined (oropharynx, olfactory mucosa, trachea, lungs, heart, kidney and cerebrum) except for the liver and olfactory bulb. These results might suggest that the first vaccination induces immunogenicity but not sterile immunity.
Rob Verkerk, Founder, Executive and Scientific Director of the Alliance for Natural Health International, a scientist who has for 30 years been exploring positive ways to span the gulfs between science and the law, between academia and industry, and between governments and their people.
Backup mirror:
Two embryonic cell lines have been used to develop COVID-19 vaccines: human embryonic kidney cells called HEK 293 and human embryonic retinal cells called PER.C6. The PER.C6 cell line is from an elective abortion in the Netherlands in 1985, and the HEK 293 cell line comes from an undisclosed source (either spontaneous miscarriage or elective abortion) in the Netherlands in about 1972.
Johnson & Johnson used PER.C6 cells in their COVID-19 vaccine development, and the Oxford/AstraZeneca vaccine used HEK 293 cells. CanSino Biologics and Gamaleya Research Institute’s Sputnik V vaccines have also used HEK 293 cells.
Moderna and Pfizer/BioNTech used HEK 293 cells in their proof-of-concept tests to see effectively take up the genetic instructions contained in these vaccines and produce the required spike protein. But human embryonic cell lines were not used to make either company’s final vaccine.
HEK 293 and PER.C6 cell lines have been genetically altered to include the part of the adenovirus instructions that trigger replication of adenoviruses. This allows the production of a large amount of the final vaccination product and allows the removal of the adenoviral replication instructions in the vaccine.